This is why during studies of therapeutic effects, researchers often combine subjective reports (such as pain scores) with objective biomarkers (such as EEG, EMG, or blood markers). While the placebo effect can negatively impact a trial or mask the efficacy of what is being tested, I think it can also be positive in that it can offer valuable insight into how perception can affect healing. Successful medical interventions rely not only on technological and pharmacological techniques, but also patient engagement, trust, and improving positive mental state.

To differentiate true drug effects from placebo effects in data, researchers rely on statistical analysis and study design—especially randomized, double-blind, placebo-controlled trials. By comparing the outcomes between the placebo and treatment groups, researchers can calculate whether the observed effects are statistically significant and clinically meaningful. If both groups improve equally, it suggests that the treatment may not have true efficacy beyond the psychological benefit of belief.

The placebo effect can indeed have negative effects on clinical trials. It can make it harder to demonstrate a drug’s true effectiveness, leading to inconclusive or misleading results. This is especially problematic in studies of conditions that have subjective outcomes, like pain or mood disorders. However, the placebo effect also provides valuable insight—it shows that patient perception, expectations, and mindset play a significant role in healing and treatment response, which can guide future approaches to patient care.

When patients are given a sugar pill and begin to present these symptoms as a result of the placebo effect, they might not improve as much as they think they are. That is, they might feel less of a specific symptom or more, but their biological response would not show much difference. Conversely, patients given the real drug will likely experience more pronounced effects upon taking a dose, which, when documented and compared to the placebo trials, will give researchers a better idea of how well the medication truly performs. In short, the placebo effect is a way to reduce any assumptions/bias by patients and measure the drug’s efficacy against a neutral, psychologically-influenced response, giving researchers a baseline to make conclusions about the effectiveness of the treatment.

It is worth noting that there are two distinct psychological responses to stimuli, especially for clinical trials. One is the aforementioned placebo effect, which involves positive responses resulting from positive expectations. The second is the nocebo effect, involving negative responses resulting from negative expectations. Both are crucial to understanding the outcomes of a prospective treatment, especially when side effects are not well understood. As such, it is plausible that some patients may not have as many positive assumptions towards the treatment as others, which influences the symptoms (or lack thereof) they will/will not present. This information gives researchers the ability to gauge the negative and positive psychological influences of the treatment to interpret and utilize the data more effectively.

I do agree that a double-blind study may help, but because a company wants to pass FDA regulations it is still possible for the people involved to skew the data analysis in one way over another. Thus, it would be beneficial for the people if the study was actually triple blind so that there is no way to tell who is receiving what medication. Limiting the unnecessary bias can help to get much more accurate data because there is less of a chance of someone manipulating the data.